Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

<< Previous

Bullboard Posts

Next >>

Post by Viking2233on Mar 27, 2024 3:34pm

177 Views

Post# 35956338

RJ Analyst

Nothing but total silence from our sole analyst at Raymond James. This analyst has not commented on number of material news releases:

1. Increased dosage study

2. FDA Approval for New Phase 2 AKI trial

3. 6 sites for Turkey

4. 3 sites for Canada

5. First dosing commenced

6. Pre-IND meeting with FDA for new re-purposed drug with new phase 2 trial to commence in the fall of 2024

7. No dilution or additional funding required at this time

8. Funally the Independent 3rd Party Perr review was published 10 days ago, which analyst has been waiting for.

There is a lot of postive catalysts here for the analyst to digest, I see a bug upgrade coming in my opinion.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages